Glow Blend research peptide is supplied to qualified Canadian institutions as a characterized, co-lyophilized laboratory material for in vitro combination studies. The vial contains GHK-Cu, BPC-157, and TB-500 at fixed manufacture ratios.

In vitro, the blend is used when an experimental design requires concurrent exposure to the copper(II) complex of Gly-His-Lys, the pentadecapeptide BPC-157, and the acetylated LKKTETQ actin-binding motif (TB-500). Component literatures describe copper-dependent extracellular-matrix and gene-expression assays for GHK-Cu, VEGFR2-proximal endothelial assays for BPC-157, and G-actin sequestration assays for TB-500. Co-lyophilization is a handling convenience; it does not establish a unique combined mechanism. Combination results should be read against single-component controls and the stated mass ratio.

The preparation is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 per vial. It contains a copper complex and should be kept desiccated at −20 °C, protected from light. PubChem identity is not assigned to the mixture as a whole; use per-component records and the lot COA.

Lots are sourced from a GMP-aligned peptide manufacturing partner. Each component is tested independently and reported at the stated HPLC purity (≥98% by HPLC per component, lot-specific) on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.